Ben Fidler

Virginia

Senior Editor at BioPharma Dive

Senior Editor at Industry Dive

Biotech Journalist; Senior Editor, BioPharma Dive. Former Deputy Biotech Editor, Xconomy.

Featured in: Favicon

biopharmadive.com Favicon

xconomy.com Favicon

healthcaredive.com Favicon

newsbreak.com Favicon

supplychaindive.com Favicon

k12dive.com Favicon

highereddive.com Favicon

medtechdive.com Favicon

bankingdive.com Favicon

substack.com + 7 more

Articles

Vinay Prasad, a physician and FDA critic, to lead agency center overseeing vaccines

1 week ago | biopharmadive.com | Ben Fidler |Jonathan Gardner

Vinay Prasad, a prolific academic and longtime critic of U.S. drug policies, was named Wednesday as the new leader of a main Food and Drug Administration office. FDA Commissioner Martin Makary announced Prasad’s appointment as the new director of the Center for Biologics Evaluation and Research, which oversees review of vaccines, blood products and some genetic medicines.
Deerfield secures more than $600M for its next biotech venture fund

1 week ago | biopharmadive.com | Ben Fidler

Deerfield Management, a prolific backer of biotechnology companies, has raised more than $600 million to invest further in young companies working on drugs, medical devices and healthcare services. The third of its kind from Deerfield, the fund will operate out of a New York City campus called “Cure” that helps nurture startups and be aided by the firm’s close collaboration with a network of nearly 30 academic institutions.
Deerfield secures more than $600M for its next biotech venture fund

1 week ago | finance.yahoo.com | Ben Fidler

Unlock stock picks and a broker-level newsfeed that powers Wall Street. Ben Fidler Mon, May 5, 2025, 6:15 AM 2 min read This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Deerfield Management, a prolific backer of biotechnology companies, has raised more than $600 million to invest further in young companies working on drugs, medical devices and healthcare services.
Acelyrin should liquidate instead of merging with Alumis, investor says

2 weeks ago | finance.yahoo.com | Ben Fidler

Unlock stock picks and a broker-level newsfeed that powers Wall Street. Ben Fidler Tue, Apr 29, 2025, 12:22 PM 3 min read In This Article: This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. A shareholder of immune drug developer Acelyin believes the company is better off shutting down and returning cash to shareholders rather than pursuing a merger with fellow biotech Alumis.
Acelyrin should liquidate instead of merging with Alumis, investor says

2 weeks ago | biopharmadive.com | Ben Fidler

A shareholder of immune drug developer Acelyin believes the company is better off shutting down and returning cash to shareholders rather than pursuing a merger with fellow biotech Alumis. Trium Capital, an England-based investment fund and Acelyrin stockholder, revealed in a regulatory filing Tuesday that it intends to vote against the planned merger after concluding it’s not in the best interest of shareholders.
Abeona cell therapy approved by FDA for rare skin condition

2 weeks ago | biopharmadive.com | Ben Fidler

The Food and Drug Administration on Tuesday approved a new treatment for a rare skin condition, teeing up a commercial battle between two cell and gene therapy developers. The agency cleared Abeona Therapeutics’ Zevaskyn for a form of epidermolysis bullosa, a rare disease that makes the skin susceptible to extensive and severe blistering.
New Akeso, Summit data stir debate on PD-1/VEGF drugs

2 weeks ago | biopharmadive.com | Ben Fidler

Dive Brief:A dual-acting cancer drug developed by Akeso and Summit Therapeutics appeared to modestly improve survival compared to Merck & Co.’s widely used cancer immunotherapy Keytruda in a clinical trial, but the difference was not large enough to determine whether the treatment is clearly better.
Caribou, in reversal, scraps autoimmune cell therapy and cuts staff

2 weeks ago | biopharmadive.com | Ben Fidler

Caribou Biosciences is laying off about a third of its staff and stopping work on an experimental lupus treatment in a gamble on the potential of a pair of cell therapies for cancer. The company on Thursday said it’s cutting 32% of its workforce, which totaled 147 employees as of March 1, according to a regulatory filing. It also announced it’s delaying planned study readouts on those two cell therapies until the second half of this year.
Enhertu combo tops standard drugs in first-line HER2 breast cancer

3 weeks ago | biopharmadive.com | Ben Fidler

A two-drug regimen involving AstraZeneca and Daiichi Sankyo’s Enhertu topped standard therapy in a large study in HER2-positive breast cancer, the companies said Monday. In a Phase 3 trial, a combination of Enhertu and the targeted therapy pertuzumab held tumors in check longer than THP, a regimen of chemotherapy and precision medicines that’s commonly used as an initial treatment for metastatic breast tumors expressing the HER2 protein.
Sanofi, Regeneron win FDA nod for Dupixent in chronic hives

3 weeks ago | biopharmadive.com | Ben Fidler

The Food and Drug Administration on Friday approved a new use for Sanofi and Regeneron’s top-selling immune disease drug Dupixent, clearing the medicine to treat a chronic skin condition that causes hives. The agency OK’d Dupixent for chronic spontaneous urticaria, an inflammatory skin disease that causes hives to form on the body and leads to severe itching, burning or swelling.